A detailed history of Css LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Css LLC holds 42,011 shares of CERE stock, worth $0. This represents 0.17% of its overall portfolio holdings.

Number of Shares
42,011
Previous 34,011 23.52%
Holding current value
$0
Previous $1.44 Million 19.49%
% of portfolio
0.17%
Previous 0.16%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.96 - $42.75 $311,680 - $342,000
8,000 Added 23.52%
42,011 $1.72 Million
Q1 2024

May 15, 2024

BUY
$40.88 - $43.27 $531,440 - $562,510
13,000 Added 61.87%
34,011 $1.44 Million
Q4 2023

Feb 14, 2024

BUY
$20.27 - $42.44 $425,892 - $891,706
21,011 New
21,011 $890,000
Q3 2021

Nov 15, 2021

SELL
$21.26 - $38.85 $415,675 - $759,595
-19,552 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$12.56 - $29.69 $245,573 - $580,498
19,552 New
19,552 $501,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Css LLC Portfolio

Follow Css LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.